Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback